Cargando…

Clinical characteristics and antimicrobial susceptibility of Bacillus cereus blood stream infections

BACKGROUND: Bacillus cereus is one of the pathogens causing nosocomial bloodstream infections (BSIs). However, few reports have documented the antimicrobial susceptibility and clinical characteristics of Bacillus cereus BSI and the importance of empirical therapy. The aim of this study was to invest...

Descripción completa

Detalles Bibliográficos
Autores principales: Ikeda, Mahoko, Yagihara, Yuka, Tatsuno, Keita, Okazaki, Mitsuhiro, Okugawa, Shu, Moriya, Kyoji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4570458/
https://www.ncbi.nlm.nih.gov/pubmed/26370137
http://dx.doi.org/10.1186/s12941-015-0104-2
_version_ 1782390214053855232
author Ikeda, Mahoko
Yagihara, Yuka
Tatsuno, Keita
Okazaki, Mitsuhiro
Okugawa, Shu
Moriya, Kyoji
author_facet Ikeda, Mahoko
Yagihara, Yuka
Tatsuno, Keita
Okazaki, Mitsuhiro
Okugawa, Shu
Moriya, Kyoji
author_sort Ikeda, Mahoko
collection PubMed
description BACKGROUND: Bacillus cereus is one of the pathogens causing nosocomial bloodstream infections (BSIs). However, few reports have documented the antimicrobial susceptibility and clinical characteristics of Bacillus cereus BSI and the importance of empirical therapy. The aim of this study was to investigate the clinical characteristics and antimicrobial susceptibility of B. cereus isolates from patients with BSI and to analyze the impact of appropriate empirical therapy on the outcome of patients with B. cereus BSI. METHODS: All adult cases of bacteremia between April 2003 and March 2012 in a teaching hospital in Tokyo, Japan were reviewed retrospectively. Clinical data were collected from the patients’ medical records and charts. Antimicrobial susceptibility testing was performed by broth microdilution method. The patients with B. cereus BSI were divided into an appropriate empirical therapy group and an inappropriate empirical therapy group. The primary outcome was all-cause mortality at 4 weeks after the start of BSI. The secondary outcome was early defervescence within 2 days after starting empirical therapy. RESULTS: There were 29 B. cereus bloodstream infection cases. No vancomycin, gentamicin, and imipenem-resistant isolates were found. However, 65.5 % were resistant to clindamycin and 10.3 % were resistant to levofloxacin. The main etiology was venous catheter-related (69 %). All-cause mortality at 4 weeks was not significantly different between the appropriate empirical therapy group (9 cases) and the inappropriate group (20 cases) in this study. However, early defervescence within 2 days after starting empirical therapy was significantly different (p = 0.032). CONCLUSIONS: The BSI of B.cereus is mostly caused by venous catheter-related infections. Appropriate empirical therapy is important to achieve early clinical resolution in B. cereus BSI. Vancomycin is one of the appropriate selections of empirical therapy for B. cereus BSI.
format Online
Article
Text
id pubmed-4570458
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-45704582015-09-16 Clinical characteristics and antimicrobial susceptibility of Bacillus cereus blood stream infections Ikeda, Mahoko Yagihara, Yuka Tatsuno, Keita Okazaki, Mitsuhiro Okugawa, Shu Moriya, Kyoji Ann Clin Microbiol Antimicrob Research BACKGROUND: Bacillus cereus is one of the pathogens causing nosocomial bloodstream infections (BSIs). However, few reports have documented the antimicrobial susceptibility and clinical characteristics of Bacillus cereus BSI and the importance of empirical therapy. The aim of this study was to investigate the clinical characteristics and antimicrobial susceptibility of B. cereus isolates from patients with BSI and to analyze the impact of appropriate empirical therapy on the outcome of patients with B. cereus BSI. METHODS: All adult cases of bacteremia between April 2003 and March 2012 in a teaching hospital in Tokyo, Japan were reviewed retrospectively. Clinical data were collected from the patients’ medical records and charts. Antimicrobial susceptibility testing was performed by broth microdilution method. The patients with B. cereus BSI were divided into an appropriate empirical therapy group and an inappropriate empirical therapy group. The primary outcome was all-cause mortality at 4 weeks after the start of BSI. The secondary outcome was early defervescence within 2 days after starting empirical therapy. RESULTS: There were 29 B. cereus bloodstream infection cases. No vancomycin, gentamicin, and imipenem-resistant isolates were found. However, 65.5 % were resistant to clindamycin and 10.3 % were resistant to levofloxacin. The main etiology was venous catheter-related (69 %). All-cause mortality at 4 weeks was not significantly different between the appropriate empirical therapy group (9 cases) and the inappropriate group (20 cases) in this study. However, early defervescence within 2 days after starting empirical therapy was significantly different (p = 0.032). CONCLUSIONS: The BSI of B.cereus is mostly caused by venous catheter-related infections. Appropriate empirical therapy is important to achieve early clinical resolution in B. cereus BSI. Vancomycin is one of the appropriate selections of empirical therapy for B. cereus BSI. BioMed Central 2015-09-15 /pmc/articles/PMC4570458/ /pubmed/26370137 http://dx.doi.org/10.1186/s12941-015-0104-2 Text en © Ikeda et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Ikeda, Mahoko
Yagihara, Yuka
Tatsuno, Keita
Okazaki, Mitsuhiro
Okugawa, Shu
Moriya, Kyoji
Clinical characteristics and antimicrobial susceptibility of Bacillus cereus blood stream infections
title Clinical characteristics and antimicrobial susceptibility of Bacillus cereus blood stream infections
title_full Clinical characteristics and antimicrobial susceptibility of Bacillus cereus blood stream infections
title_fullStr Clinical characteristics and antimicrobial susceptibility of Bacillus cereus blood stream infections
title_full_unstemmed Clinical characteristics and antimicrobial susceptibility of Bacillus cereus blood stream infections
title_short Clinical characteristics and antimicrobial susceptibility of Bacillus cereus blood stream infections
title_sort clinical characteristics and antimicrobial susceptibility of bacillus cereus blood stream infections
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4570458/
https://www.ncbi.nlm.nih.gov/pubmed/26370137
http://dx.doi.org/10.1186/s12941-015-0104-2
work_keys_str_mv AT ikedamahoko clinicalcharacteristicsandantimicrobialsusceptibilityofbacilluscereusbloodstreaminfections
AT yagiharayuka clinicalcharacteristicsandantimicrobialsusceptibilityofbacilluscereusbloodstreaminfections
AT tatsunokeita clinicalcharacteristicsandantimicrobialsusceptibilityofbacilluscereusbloodstreaminfections
AT okazakimitsuhiro clinicalcharacteristicsandantimicrobialsusceptibilityofbacilluscereusbloodstreaminfections
AT okugawashu clinicalcharacteristicsandantimicrobialsusceptibilityofbacilluscereusbloodstreaminfections
AT moriyakyoji clinicalcharacteristicsandantimicrobialsusceptibilityofbacilluscereusbloodstreaminfections